.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Cerilliant
Argus Health
Colorcon
Farmers Insurance
McKinsey
UBS
Baxter
Moodys
Accenture

Generated: November 19, 2017

DrugPatentWatch Database Preview

Avibactam sodium; ceftazidime - Generic Drug Details

« Back to Dashboard

What are the generic sources for avibactam sodium; ceftazidime and what is the scope of avibactam sodium; ceftazidime patent protection?

Avibactam sodium; ceftazidime
is the generic ingredient in one branded drug marketed by Cerexa and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Avibactam sodium; ceftazidime has one hundred and fifty-seven patent family members in fifty-two countries and three supplementary protection certificates in three countries.

One supplier is listed for this compound.

Summary for avibactam sodium; ceftazidime

Pharmacology for avibactam sodium; ceftazidime

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cerexa
AVYCAZ
avibactam sodium; ceftazidime
POWDER;IV (INFUSION)206494-001Feb 25, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Cerexa
AVYCAZ
avibactam sodium; ceftazidime
POWDER;IV (INFUSION)206494-001Feb 25, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Cerexa
AVYCAZ
avibactam sodium; ceftazidime
POWDER;IV (INFUSION)206494-001Feb 25, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Cerexa
AVYCAZ
avibactam sodium; ceftazidime
POWDER;IV (INFUSION)206494-001Feb 25, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Cerexa
AVYCAZ
avibactam sodium; ceftazidime
POWDER;IV (INFUSION)206494-001Feb 25, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Cerexa
AVYCAZ
avibactam sodium; ceftazidime
POWDER;IV (INFUSION)206494-001Feb 25, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Cerexa
AVYCAZ
avibactam sodium; ceftazidime
POWDER;IV (INFUSION)206494-001Feb 25, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Cerexa
AVYCAZ
avibactam sodium; ceftazidime
POWDER;IV (INFUSION)206494-001Feb 25, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: avibactam sodium; ceftazidime

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,062,053Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-Diazabicyclo[3,2,1]octane-2-carboxamide sodium salt► Subscribe
7,638,529Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents► Subscribe
9,580,424Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt► Subscribe
7,732,610Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents► Subscribe
8,829,191Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: avibactam sodium; ceftazidime

Country Document Number Estimated Expiration
Mexico2013014114► Subscribe
Japan6072540► Subscribe
Brazil0112986► Subscribe
European Patent Office2279737► Subscribe
CroatiaP20040686► Subscribe
Argentina086972► Subscribe
Japan2017036307► Subscribe
Japan2004505088► Subscribe
European Patent Office2721005► Subscribe
Denmark1480644► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: AVIBACTAM SODIUM; CEFTAZIDIME

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2016037Lithuania► SubscribePRODUCT NAME: CEFTAZIDIMAS + AVIBAKTAMAS; REGISTRATION NO/DATE: EU/1/16/1109/001 20160624
2016 00059Denmark► SubscribePRODUCT NAME: FARMACEUTISK BLANDING ELLER SAMMENSAETNING DER SOM AKTIVE BESTANDDELE DERAF, HERUNDER CEFTAZIDIMPENTAHYDRAT OG AVIBACTAMNATRIUM; REG. NO/DATE: EU/1/16/1109 20160628
0847Netherlands► SubscribePRODUCT NAME: FARMACEUTISCH MENGSEL OF SAMENSTEL DAT DE VOLGENDE WERKZAME BESTANDDELEN BEVAT: (1) CEFTAZIDIM OF EEN ZOUT ERVAN, EN (2) AVIBACTAM OF EEN ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/16/1109/001 20160628
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Fuji
Accenture
Express Scripts
Deloitte
Teva
US Army
Boehringer Ingelheim
QuintilesIMS
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot